{"id":517193,"date":"2021-07-23T16:33:26","date_gmt":"2021-07-23T20:33:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-data-from-aduhelm-and-alzheimers-disease-portfolio-at-2021-alzheimers-association-international-conference\/"},"modified":"2021-07-23T16:33:26","modified_gmt":"2021-07-23T20:33:26","slug":"biogen-to-present-data-from-aduhelm-and-alzheimers-disease-portfolio-at-2021-alzheimers-association-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-data-from-aduhelm-and-alzheimers-disease-portfolio-at-2021-alzheimers-association-international-conference\/","title":{"rendered":"Biogen to Present Data from ADUHELM and Alzheimer\u2019s Disease Portfolio at 2021 Alzheimer\u2019s Association International Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) — Biogen Inc.<\/a> (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer\u2019s disease clinical development portfolio at the Alzheimer\u2019s Association International Conference (AAIC), which will be held in Denver, Colorado and online July 26-30, 2021. The company\u2019s contributions to AAIC will include several presentations highlighting data on ADUHELM\u2122 (aducanumab-avwa) injection 100 mg\/mL solution, which was recently granted accelerated approval by the U.S. Food and Drug Administration (FDA) as a treatment for Alzheimer\u2019s disease, as well as its broader Alzheimer\u2019s disease portfolio and research in the field.<\/p>\n

ADUHELM is indicated for the treatment of Alzheimer\u2019s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).<\/p>\n

Data presentations on ADUHELM will include presentations on multiple topics, including results of an analysis of the PRIME, EMERGE and ENGAGE studies on the correlation between reductions in biomarkers of Alzheimer\u2019s disease and clinical decline after treatment with ADUHELM. The company\u2019s contributions to the congress include four presentations on ADUHELM data and a total of 11 abstracts.<\/p>\n

The company will also lead a late-breaking presentation on the design of the real-world observational Phase 4 study in Alzheimer\u2019s disease, a prospective registry of ADUHELM, called International Collaboration for Real-World Evidence in Alzheimer\u2019s Disease (ICARE AD-US). ICARE AD-US is focused on collecting real-world, long-term effectiveness and safety data on ADUHELM.<\/p>\n

Biogen\u2019s commitment to generate new data about ADUHELM includes three components: the ICARE AD study, the ongoing redosing study, EMBARK, for eligible patients previously enrolled in aducanumab trials, and the upcoming confirmatory, controlled Phase 4 trial that is part of the post-marketing requirement in connection with ADUHELM\u2019s accelerated approval.<\/p>\n

Posters and presentations will be available for 30 days on the AAIC conference website. Biogen will also post the aducanumab and BIIB080 posters and presentations on the investors section of its website at investors.biogen.com at the times indicated below.<\/p>\n

\n
\n Biogen Oral and Poster Presentations:<\/em>
\n <\/strong>\n <\/p>\n